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Sodium channel drugsVoltage-gated sodium channels (Navs) are an important family of transmembrane ion channel proteins
and Nav drug discovery is an exciting ﬁeld. Pharmaceutical investment in Navs for pain therapeutics
has expanded exponentially due to genetic data such as SCN10A mutations and an improved ability to
establish an effective screen sequence for example IonWorks Barracuda, Synchropatch and Qube.
Moreover, emerging clinical data (AZD-3161, XEN402, CNV1014802, PF-05089771, PF-04531083)
combined with recent breakthroughs in Nav structural biology pave the way for a future of fruitful
prospective Nav drug discovery.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Voltage-gated sodium channels (Nav) are a family of transmem-
brane ion channel proteins. Structurally, they are members of the
6-TM ion channel family and are composed of a transmembrane
a-subunit of approximately 260 kDa and several associated trans-
membrane b-subunits of lower molecular weight. The family com-
prises nine members Nav1.1-Nav1.9 and related NaX. Navs are
involved in Na+ ion conduction across cell membranes during cell
membrane depolarization. If cell membrane depolarization reaches
a threshold value Nav channels open to allow Na+ ions to ﬂow into
cells. This movement creates action potentials and nerve impulses
in electrically excitable cells, for example neurons, and affects
many functions for example the peripheral and central nervous
system, cardiac and skeletal muscle etc. Blockade of Navs has been
successfully accomplished in the clinic to enable control of patho-
logical ﬁring patterns that occur in a diverse range of conditions
such as chronic pain, epilepsy, and cardiac arrhythmias. In this
review we will discuss recent advances in the ﬁeld of Nav drug dis-
covery for the treatment of pain. In particular progress in biology,
structural biology, assay technology, inhibitor development and
clinical success will be discussed.
Sodium channel topology and structure: Structural studies of
6TM-topology ion channels date back to the late 1980s, when
Numa et al. successfully cloned a-subunits of sodium channels.1,2
According to sequence analysis, Nav a-subunits are composed ofapproximately 2000 amino acids which assemble into four distinct
domains (D1–D4), each of which consists of 6TM a-helices (S1–S6)
(Fig. 1). Two helices (S5–S6) from each domain contribute towards
formation of the channel pore which is responsible for Na ion con-
duction. The S1–S4 helices from each domain form a voltage sensor
which works as a sensor of change in voltage across the cell mem-
brane. Consequently, the pore is formed from eight helices and
there are four voltage sensors surrounding the pore. Between the
pore-forming helices (S5–S6) from each domain there is an
extended P-loop which acts to form the Na ion selectivity ﬁlter.
Other voltage-gated channels, Kv and Cav, share common topology
and mechanism of activation with the Nav class.3
Recently, structural understanding of this class of ion channels
has been drastically improved due to the publication of site direc-
ted mutagenesis work and several crystal structures; a KV1.2/2.1
chimera crystal structure by MacKinnon4 and multiple NavAb bac-
terial sodium channel apo crystal structures from Catterall.5,6
Interestingly, these structures complement each other by appear-
ing to sample several states of the NavAb channel. By comparison
of the structural differences these structures provide valuable
insight into gating mechanisms and conformational changes which
occur to open the channel pore to ion ﬂux.5 These studies also
highlight fenestration regions within the channel pore that may
constitute potential binding sites for small molecule modulators.
However, to date there have been no reported co-crystal structures
of any sodium channel proteins with small molecule or toxin mol-
ecules bound.
Figure 1. (a) NaV channel structural topology. Domains D1–D4 are represented in different colors while b subunits are shown in gray. Transmembrane segments (S1–S6)
labelled together with graphical representation of P-loops. (b) Side view; (c) Top view of voltage-gated sodium channel from the bacterium Arcobacter butzleri (NavAb–PDB
code 3RVY)5,6 with highlighted postulated toxin binding sites (1–6), local anesthetic binding site and signiﬁcant structural features.
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structures, the ﬁeld is also beneﬁting from advances in computa-
tional modeling and molecular dynamics to understand the open-
ing/closing mechanism of voltage-gated channels. For example, a
publication from Jensen et al., which describes micro second order
molecular dynamics for the related KV1.2/2.1 channels, suggests
that these channels close with a hydrophobic collapse of a pore
residue, which is followed by movement of the voltage-sensor
domain towards the pore.7,8 Conversely, in the opening process,
the voltage sensor moves outward ﬁrst, which pulls the pore
domain to open.
Overall, the combination of structural, mutagenesis and compu-
tational studies have been used to build an understanding of Nav
channel conformational gating and function. At a simplistic level,
Nav channels are believed to exist in three states characterized
by conduction behavior at different voltage potentials: open,
closed (resting) and inactivated. At a resting trans-membrane
potential, the channels are in a non-conducting closed state. When
membrane potential is decreased (depolarization) the voltage sen-
sors (S1–S4) move outward in a rotational movement, pulling the
pore open for a short period (<1 ms). Subsequently the channel
then moves via a combination of fast- or slow-inactivation pro-
cesses into a non-conductive inactivated state. It is currently
believed that a speciﬁc loop between D3 and D4 termed the inac-
tivation gate is responsible for fast inactivation. Finally, an increase
in membrane potential (hyperpolarization) causes the Nav chan-
nels to return to the resting state.
Nav channel genetics and biology: Nav channels as pain targets
gained traction with the recognition that some Nav subtypes
showed preferential or exclusive expression in peripheral sensoryneurons.9 While peripheral sensory neurons express nearly all
Nav subtypes at some level, there are three subtypes, Nav1.7,
Nav1.8, and Nav1.9 which are enriched in peripheral neurons of
the trigeminal and dorsal root ganglia (DRG). Of these, Nav1.7 is
the most broadly expressed in DRG neurons, while expression of
Nav1.8 and Nav1.9 is largely restricted to the subset of small and
medium neurons which are thought to represent the majority of
nociceptors. The role of Nav1.7, Nav1.8, and Nav1.9 in pain signaling
has been well established in pharmacological, molecular and
genetic studies with preclinical species.10 Human validation of
these targets had lagged behind the animal studies until the dis-
covery that inherited erythromelalgia (IEM) is causally linked to
missense mutations in Nav1.7.11 Since this discovery, the family
of Nav channelopathies has expanded in two important areas. First,
the link between Nav1.7 variants and clinical pain syndromes now
includes a subset of idiopathic small ﬁber neuropathies, a disorder
which affects millions of patients. Second, additional Nav related
channelopathies have been discovered which are causally linked
to Nav1.8 and Nav1.9. These studies provide evidence for the con-
tribution of each subtype of peripherally expressed Nav channel
to pain signaling.
Nav1.7: The ﬁrst Nav channelopathy linked to pain to be identi-
ﬁed was inherited erythromelalgia (IEM). IEM is characterized by
extreme burning pain, typically in the distal extremities, which is
triggered by moderate increases in temperature. Electrophysiolog-
ical characterization of the mutant channels revealed a gain-
of-function phenotype in channel activation, consistent with the
pathological sensitivity to heating. To date, twenty SCN9A variants
have been linked to IEM and have consistently shown a gain of
function phenotype and demonstrated the ability to produce
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ond rare genetic disease, paroxysmal extreme pain disorder
(PEPD), has also been linked to SCN9A gene mutations.13 PEPD also
produces a burning pain accompanied by ﬂushing of the skin but is
considered clinically distinct from IEM. Electrophysiological
characterization of PEPD mutations similarly revealed a gain-
of-function phenotype but they disrupt fast-inactivation of
Nav1.7, preventing the channel from closing properly, and produce
prolonged ﬂow of sodium current and resurgent currents upon
repolarization.14
Following the discovery of a causal link between Nav1.7 func-
tion and disorders of enhanced or aberrant pain, another rare dis-
order, congenital insensitivity to pain (CIP), was linked to
mutations of SCN9A.15 These recessive mutations result in a com-
plete loss of functional Nav1.7 channels and an apparent complete
loss of ability to sense painful stimuli. Affected individuals report
no sensation of pain which can often lead to a signiﬁcant negative
impact on overall health. The most recent pain related disorder to
be linked to SCN9A is idiopathic small ﬁber neuropathy (I-SFN), a
common adult-onset pain disorder. The family of small-ﬁber neur-
opathies is extensive, potentially affecting upwards of 40 million
Americans, with nearly 50% of cases classiﬁed as idiopathic.16
Nav1.7 variants have been found in 28% of a group of patients diag-
nosed with idiopathic small ﬁber neuropathy.17 Electrophysiologi-
cal characterization of these mutant channels also showed a gain of
function affecting either activation or inactivation, resulting in
increased excitability of DRG neurons.
Nav1.8: The tetrodotoxin resistant Nav1.8 channel has been
shown to be the primary contributor of sodium ﬂux during the
upstroke of the action potential of DRG neurons.18 In follow-up
studies of I-SFN, a group of patients negative for mutations of the
SCN9A gene were subjected to exome sequencing of the SCN10A
gene which encodes the Nav1.8 channel.19 Three mutations were
identiﬁed which had a high likelihood of altering Nav1.8 function.
Two of these mutations, L554P and A1304T, were shown to
enhance recovery from fast inactivation and hyperpolarize the
voltage dependence of activation, respectively. As with Nav1.7,
these biophysical changes were predicted to be pro-excitatory
and both channels were subsequently demonstrated to produce
hyperexcitability of DRG neurons.
Nav1.9: The three most recently discovered Nav channelopathies
are associated with mutations of the Nav1.9 channel. Nav1.9 is bio-
physically distinct from other Nav channels, displaying slow activa-
tion and inactivation properties. Consequently, Nav1.9 does not
directly contribute to the action potential waveform, but is thought
to provide a variable background Na conductance that is important
for determination of resting membrane potential and membrane
excitability.20
Two large Chinese families with episodic pain, primarily of the
distal extremities, were found to harbormissensemutations within
the SCN11A gene.21 Electrophysiological studies of the mutant
channels showed no signiﬁcant alteration of activation or inactiva-
tion properties but did reveal enhanced current amplitude when
compared to the wild type Nav1.9 channel. A different, novel
Nav1.9 missense mutation results in gain of channel function but
gives a seemingly confounding clinical phenotype of complete
insensitivity to pain.22 Despite the Nav1.9 gain of function, the loss
of pain sensitivity phenotype is presumed to arise from inactivation
of Nav channels responsible for action potential propagation result-
ing in an inability to sustain ﬁring and conduction block. A recent
study involving three hundred and forty ﬁve patients with periph-
eral neuropathy but withoutmutations in SCN9A and SCN10A iden-
tiﬁed missense mutations of Nav1.9 as a cause of painful peripheral
neuropathy. Eight variants of SCN11A were identiﬁed in twelve
patients. Functional proﬁling by electrophysiological recordings
showed that these Nav1.9 mutations confer gain-of-functionattributes to the channel, depolarize resting membrane potential
of DRG neurons, enhance spontaneous ﬁring, and increase evoked
ﬁring of these neurons.23
Sodium channel toxin-derived modulators: Numerous natural
toxins and synthetic derivatives are known to modulate sodium
channels. These include both polar small molecule toxins and a
variety of peptide-based venom toxins. Interestingly these toxins
cover a wide range of structural classes and have been isolated
frommany different animal sources including ﬁsh, shellﬁsh, spider,
snail, scorpion and centipede venoms.24 All known sodium
channels modulators are believed to act via binding to sites on
the a-subunits. Currently there are at least six different binding
sites known for toxins, classiﬁed as Neurotoxin receptor site 1–6
(Fig. 1).
Site 1 binds non-peptidic neurotoxins tetrodotoxin (TTX), saxi-
toxin and also several peptide toxins such as cone snail l-conotox-
ins (Fig. 2). The binding site for these toxins is formed by amino
acids on the pore and selectivity ﬁlter loops on the extracellular
end of the pore. As a result, site 1 toxins bind to directly block
the pore to Na+ access. Interestingly, the sensitivity of the nine
sodium channels to TTX blockade has been used to divide the fam-
ily into two classes TTX-S sensitive IC50 <30 nM (Navs 1.1, 1.2, 1.3,
1.4, 1.6, 1.7) and TTX-R resistant IC50 >30 nM (Navs 1.5, 1.8). This
TTX afﬁnity difference between the Navs is believed to be
explained by the presence or absence of a key cysteine residue in
the TTX-binding site.25
Site 2 binds a group of lipid-soluble toxins, including batracho-
toxin, veratridine, aconotine, antillatoxin, hoiamides and grayano-
toxin all of which increase activation of Nav channels by binding to
the open conformation of the channels leading to persistent activa-
tion (Fig. 2). A combination of mutagenesis and photoafﬁnity label-
ing experiments suggest that transmembrane segments S6 from
D1 and D4 play a role in the binding site of batrachotoxin.24
Site 3 binds peptidic a-scorpion and sea anemone anthopleurin
toxins which work to slow the rate that the sodium channel moves
from open to inactive states. These peptides are believed to bind to
a site that is formed from the S3 to S4 loop at the extracellular end
of the D4 voltage sensor as demonstrated by site-directed
mutagenesis.24
Site 4 is known to bind b-scorpion toxins at the S3–S4 loop on
the extracellular side of the D2 voltage sensor. These toxins act as
gating modiﬁers that shift the activation threshold to more nega-
tive membrane potentials. Conversely, several spider toxins (e.g.,
ProTx-II, HwTx-IV) and a centipede toxin have been recently
described to bind to this site and inhibit sodium channels by mod-
ifying the voltage dependence of channel activation towards more
positive values.24,26,27
Site 5 binds the complex lipophilic polyether marine toxins
brevetoxin and ciguatoxins that have been implicated in a number
of effects including inhibition of channel opening and shift of acti-
vation towards hyperpolarized potentials. Pore helices S5 from D1
and S6 from D4 have been implicated in the binding of brevetoxin
as highlighted by photoafﬁnity labeling studies.24
Site 6 binds d-conotoxins which are known to slow the rate of
inactivation in a similar manner to the a-scorpion toxins. The loca-
tion of this binding site is not well understood but is believed to be
the extracellular part of the D4 voltage sensor, adjacent to site 3.24
Recently there has been increased activity in the arena of syn-
thetic toxins with the objective of generating toxin-based tools
and therapeutics. Most notably, site 1 toxin tetrodotoxin (TTX)
has been advanced into clinical trials by Wex Pharmaceuticals
and is currently progressing in Phase III trials for cancer and che-
motherapy-related pain. In addition, there have been several
papers and patents outlining synthetic analogues of site 4 toxin
inhibitors, most notably the synthesis of potent Nav1.7 selective
HwTx-IV analogs.28–30
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Figure 2. Selected toxin modulators.
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developed to enable sodium and calcium channel drug discovery.
In fact, the investigation of ion channels has always been challeng-
ing, with data being limited to non-functional information, such as
binding and FRET based data or functional electrophysiology data
where screening throughput is often at the expense of quality.
Although developments in the ﬁeld of automated electrophysiol-
ogy now allow for its use in higher throughput screening cascades
through to more in depth biophysical characterization of channel
interactions, the biggest limitation remains with how to interpret
this electrophysiology data. The range of platforms available and
subtle differences in the protocol designs are so varied that com-
paring information across screening platforms is an additional sig-
niﬁcant challenge.
Current technologies: The conventional patch clamp approach
using a glass pipette to patch a single cell is considered the gold
standard in electrophysiological measurements and is relied upon
for in depth biophysical characterization. However, planar patch
clamp technologies are generally the ﬁrst choice as a screening
platform as they allow for electrophysiological recordings to be
made from multiple cells simultaneously, with varying levels of
quality and throughput.31 Giga seal platforms such as 16 well
PatchXpress and 48 well Qpatch offer high quality, low through-
put data whilst the 384 well IonWorks system deliver high
throughput, lower quality data. By combining these screening
technologies they allow for a comprehensive screening cascade.32
Recent advances with the IonWorks Barracuda, Synchropatch
and Qube provide giga seal quality data in a 384 well format, con-
tinuous voltage control and faster ﬂuid exchanges. This permits a
functional measure of compound activity at a much earlier stage
in the drug discovery cascade.
Non-functional assays: One of the ﬁrst methodologies employed
for ion channel investigation was radioligand binding. Whilst this
screen has been used for many years to triage ion channel ligands,
it has some limitations, for example, the need for highly speciﬁc and
selective ligands alongwith difﬁculty in functional interpretation of
binding data unless there is conﬁdence in the functional impor-
tance of the binding site.33 Moreover, for targets where generating
stable cell lines is difﬁcult, ﬂuorescence based assays are sometimes
the only option available for high throughout assessment.34
Aims for the future: There are still many technical limitations
around the quality of automated patch clamp techniques, such as
access resistance and compensation, which require much improve-
ment before automated patch clamp techniques will be able to
replace conventional patch electrophysiology.35 Despite this, the
future of screening technologies for ion channel drug discovery
promises to be an exciting one.36 The real breakthrough will come
as more clinical data becomes available to interpret which in-vitro
assays or protocols are the most predictive of clinical outcomes.
Recent advances in current clamp technology on the automated
platforms should help with this in-vitro to clinical in-vivo transla-
tion by allowing measurement of effects on excitability.Small molecule modulators: Small molecule binding sites:
Although sodium channels have six known binding sites for neuro-
toxins, extensive evidence suggests most small molecule inhibitors
of Nav channels bind within the pore region for example local anes-
thetic, antiepileptic and antiarrhythmic agents (Fig. 1).37 Elegant
site directed mutagenesis experiments suggested that these agents
interact with amino acid residues within the inner cavity of the
channel pore (S6 in D4), and this binding site has been named
the local anesthetic (LA) binding site.38 The LA binding site is
highly conserved across Nav channels and most likely accounts
for the lack of subtype selectivity for most clinically used sodium
channel blockers. Clinically, non-selective modulation of sodium
channels can be associated with undesirable side effects for
example cardiac toxicity due to inhibition of Nav1.5 channels.39
Strategies to identify inhibitors with improved sodium channel
subtype selectivity and side effect proﬁle include developing bind-
ing assays and site directed mutagenesis studies to elucidate and
exploit novel binding sites. Several radioactively labeled toxin
binding assays have been developed offering new tools in the
search for novel sodium channel blockers (Fig. 2). Historically, a
[3H]batrachotoxin (3H-BTX 3) binding assay has been utilized to
discover novel sodium channel inhibitors due to the perceived
binding overlap of this toxin site with the ‘druggable’ LA site.40
However, the realization that inhibitors binding to alternative sites
may offer greater selectivity has driven more recent binding assay
development towards radiolabelling alternative peptides. For
example, radiolabelled spider venom peptides 125I-Pro-Tx-II41
and 125I-HwTx-IV28 may provide the necessary assays to identify
and design novel peptides and potentially small molecules with
improved potency and/or subtype selectivity.
Merck have described a small molecule binding assay based on
a high afﬁnity 1-benzazepin-2-ones series with the belief that
enhanced channel interactions could pave the way for seeking
novel chemotypes with improved subtype selectivity ([3H]BNZA,
Fig. 3).42 However, most clinical LA site binders compete for
[3H]BNZA (4) binding to Nav channels consistent with overlapping
binding sites and the benzazepine series itself only displays mod-
est levels of Nav1.5 selectivity. Interestingly, Amgen have demon-
strated that a representative compound from a triazene series
does not displace 3H-BTX (3) but does displace tritiated triazene
structural analog 5 (Fig. 3).43 Furthermore, the local anesthetic tet-
racaine inhibits 3H-BTX (3) binding but does not affect 3H-triazene
5 binding consistent with separate interaction sites for this novel
series compared with the local anesthetics. Examples from this ser-
ies also demonstrate good levels of selectivity for Nav1.7 over the
cardiac Nav1.5 and hERG channels. In contrast, A-803467 (6), a
small molecule inhibitor from Icagen/Abbott, displays excellent
levels of Nav1.8 selectivity over other Nav channel subtypes yet
its binding site appears to overlap with that of local anesthetic tet-
racaine.44 More recently, a unique interaction region on the D4
voltage sensor that is structurally distinct from the channel pore,
has been described.45 Using both chimeras and single point
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types have been reported. These compounds interact with ‘extra-
cellular’ facing regions of the channel which appear to be the
major determinants of Nav subtype selectivity (e.g., PF-04856264
(7), Nav1.7 IC50 28 nM, Nav1.5 IC50 >10000 nM).
Small molecule patent literature: Over the past two years, there
have been few new disclosures of Nav1.8 inhibitors in the literature
since previous reviews and no new disclosures for selective Nav1.3
or Nav1.9 inhibitors. A greater number of patent applications for
compounds claiming Nav1.7 inhibition or mixed Nav1.7 activity
with other sodium channels for treating pain have been published.
There have also been several disclosures of compounds as sodium
channel inhibitors for treating pain that do not provide a descrip-
tion of the sodium channel tested. Representative examples from
patent applications publishing over the past two years are com-
piled in Figures 4–14 along with biological activity, subtype selec-
tivity and screening platform data if available. It is prudent to note
that screening technologies and protocols vary signiﬁcantly across
the pharmaceutical industry.
Pﬁzer has recently disclosed two new series of potent Nav1.8
inhibitors, an arylimidazole and a benzimidazole series (Fig. 4).
No selectivity data was presented in these patent applications.
In terms of Nav1.7 selective inhibition, Pﬁzer and Pﬁzer/Icagen
have published patents with compounds containing aryloxysulf-
onamides and sulfonylated amides.46–48 Pﬁzer has since made
additional disclosures of aryloxysulfonylated amides and acy-
lsulfonyl ureas and arylindazole sulfonylated amides (Fig. 5). Selec-
tivity data is not disclosed in these patents, however it is reported
that the lipophilic acid PF-04856264 (7) is highly Nav1.7 selective
over Nav1.5 (Fig. 3).45 A number of other companies have recently
ﬁled patent applications for compounds occupying similar physio-
chemical space as the compounds described by Pﬁzer. These com-
panies include Amgen, Daiichi Sankyo, Merck, Xenon, DaeWoong
and joint ﬁlings between Xenon and Genetech. Amgen have dis-
closed several series of compounds with bicyclic core sulfonamides
(Fig. 6). These compounds are potent Nav1.7 inhibitors with selec-
tivity against Nav1.5. Xenon has disclosed potent zwitterionic
substituted piperazine and piperizine methyleneoxy arylsulfon-
amides, and a series of aryloxysulfonamides (Fig. 7). Nav1.5 data
for multiple examples indicate that these compounds are Nav1.7
selective. In joint applications between Xenon and Genetech aryl-
oxysulfonylated amides and acylsulfonyl ureas have been reportedN
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Figure 4. Nav1.8 modulators developed by Pﬁzer; EIC50 = estimated IC50.47,61(Fig. 8). In these applications Nav1.7 membrane binding data is
provided in addition to the Nav1.7 and Nav1.5 PatchXpress (PX)
data that demonstrates selectivity for many of these compounds.
Merck has claimed benzo-oxazolone core sulfonamides that are
potent Nav1.7 inhibitors with good selectivity against Nav1.5
(Fig. 9). Many of the compounds are zwitterionic. The compounds
from Daiichi Sankyo employ a cycloalkyloxyaryl-sulfonamide to
deliver potent Nav1.7 inhibitors as determined by testing on the
IonWorks Quattro™ (IWQ) platform (Fig. 9).
Purdue has continued to patent extensively on the aryloxy-
biarylmotifs with multiple ﬁlings over the past two years
(Fig. 10). Nav1.7 activity is reported but no subtype selectivity data
is provided. They employ a range of polar groups on the distal ring
of the biaryl, and it will be interesting to see what effect these sub-
stitutions have on selectivity, central nervous system (CNS) pene-
tration and solubility. Other companies reporting compounds
with Nav1.7 activity (with no subtype selectivity data provided)
are shown in Figure 11. The representative examples from Zalicus,
Schering and Shionogi appear to be moderate Nav1.7 modulators.
RaQualia have ﬁled a number of applications with substituted het-
eroaryl cores that are claimed as TTX-S inhibitors. Nav1.3, Nav1.5
and Nav1.7 data were also reported (Fig. 12). The biaryl spiro-
pyrrolidine-lactams reported by Convergence are moderately
potent against Nav1.7 as tested on the QPatch platform at the
half-maximal voltage for steady state inactivation protocol. More-
over, pIC50 values at 90 mV are also provided. Two examples
shown in Figure 13 are claimed in multiple ﬁlings by Convergence.
The spiro-piperidine compounds published by Vertex claim activ-
ity towards ‘a sodium channel’ and appear to be related to previous
applications (Fig. 14).49
Compounds in clinical development: A number of orally adminis-
tered sodium channel modulators have been reported to enter clin-
ical trials for the treatment of pain (Table 1). CNV1014802 (8) is a
novel oral state-dependent sodium channel blocker being devel-
oped by Convergence (Fig. 15). CNV1014802 has completed Phase
II trials for lumbosacral radiculopathy and is in Phase II trials for
trigeminal neuralgia. Furthermore, CNV1014802 was granted
orphan drug designation in 2013 by the US Food and Drug Admin-
istration (FDA) for the treatment of trigeminal neuralgia.50 Pﬁzer
have advanced several Nav1.7 and Nav1.8 selective compounds into
Phase I/II clinical trials. PF-05089771 has completed Phase II clin-
ical trials of third molar extraction and primary inherited erythro-
melalgia.51,52 Pﬁzer has also reported advancing selective Nav1.8
blockers including PF-04531083.53 Dainippon Sumitomo recently
progressed a Nav1.7/Nav1.8 compound DSP-2230 into Phase I for
neuropathic pain.54 NKTR-171 is a sodium channel blocker in
Phase I by Nektar Therapeutics for the treatment of peripheral neu-
ropathic pain. NKTR-171 is sodium channel unselective although it
exhibits peripheral restriction together with state and use depen-
dence leading to functional selectivity.55
Some therapeutic agents have been reported to enter clinical
trials for the treatment of pain that proceed via a non-oral admin-
istration route. AstraZeneca has reported the effects of intradermal
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Tetrodotoxin (TTX, Fig. 2), an injectable non-narcotic marine
neurotoxin, is being advanced in Phase II/III clinical trials for thetreatment of cancer related pain. TTX was originally developed at
Wex Pharmaceuticals followed by a collaboration with Esteve.29,57
XEN402 (9) is a novel topical Nav1.7 sodium channel blocker in
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3696 S. K. Bagal et al. / Bioorg. Med. Chem. Lett. 24 (2014) 3690–3699Phase II clinical evaluation at Xenon Pharmaceuticals. Xenon has
reported positive Phase II readouts where topical application of
XEN402 reduced pain in patients suffering from primary erythro-
melalgia and in patients suffering from postherpetic neuralgia.58,59
Results from an oral Phase II study with XEN402 suggested positive
effects in the dental model of acute inﬂammatory pain. XEN402
has been granted orphan drug designation by the FDA for the treat-
ment of erythromelalgia. Moreover, the product was licensed toTeva by Xenon Pharmaceuticals in 2012 on a worldwide basis for
the treatment of pain and is now called TV-45070. XEN403 has
been presented as a backup candidate of XEN402/TV-45070 for
the potential oral treatment of pain, although there have been no
recent updates.60
The accurate isoform selectivity and biophysical characteristics
of many of the clinical compounds described above that are
advancing through clinical efﬁcacy trials have not been disclosed.
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selectivity will achieve therapeutic utility with decreased cardio-
vascular and CNS risks.
Outlook and summary: Sodium channel drug discovery is an
exciting and developing ﬁeld of science. It appears that pharma-
ceutical investment in this target class in the search for pain ther-
apeutics is driven by two major parameters: genetic data linking
Nav mutations to pain phenotypes for target validation and the
ability to express stable cell lines and establish effective screen
sequences. For example, recent Nav1.9 genetic data may beexpected to lead to an explosive pharmaceutical effort in the same
vein as Nav1.7. However, this work will be signiﬁcantly hindered
until stable Nav1.9 expressing cell lines are available for adequate
screening. Screening methods vary greatly across the pharmaceuti-
cal sector and it is often unclear which protocol is the most predic-
tive for efﬁcacy in a clinical disease setting. Hopefully, as clinical
data emerge this screening effort can be condensed to identify
the most relevant approach for preclinical in-vitro to clinical in-
vivo translation. Finally, prospective Nav drug design is compli-
cated by the variety of available Nav binding sites across multiple
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Figure 14. Compounds developed by Vertex with reported IC50 <2 lM inhibition against a sodium channel.49,96–98
Table 1
Nav channel modulators that have reached clinical development for the treatment of pain
Compound Company Pharmacology Phase Therapeutic indication Refs.
AZD3161 AstraZeneca Nav1.7 I Neuropathic/Inﬂammatory pain (IV, intradermal) 56
CNV1014802 Convergence Nav1.7 II Neuropathic pain 50
Trigeminal neuralgia (oral)
DSP-2230 Dainippon Sumitomo Nav1.7/1.8 I Neuropathic pain (oral) 54
NKTR-171 Nektar Broad Nav I Neuropathic pain (oral) 55
PF-04531083 Pﬁzer Nav1.8 I Neuropathic/Inﬂammatory pain (oral) 53
PF-05089771 Pﬁzer Nav1.7 II Neuropathic/Inﬂammatory pain erythromelalgia (oral) 52
TTX WEX TTX-S Nav III Neuropathic/Inﬂammatory cancer pain (IV) 57
XEN402 Xenon/Teva Nav1.7 II Neuropathic/Inﬂammatory pain erythromelalgia (topical) 58–59
XEN403 Xenon Nav1.7 I Neuropathic/Inﬂammatory pain erythromelalgia (oral) 60
O
N
O
O
O
O
F3C
Xenon
XEN402 (9)
Convergence
CNV1014802 (8)
N
H
O
F
O
NH2
N
N
O
O
N
H
O
N
O CF3
Astrazeneca
AZD3161 (10)
Figure 15. Nav channel modulators in clinical development for the treatment of pain.
3698 S. K. Bagal et al. / Bioorg. Med. Chem. Lett. 24 (2014) 3690–3699ion channel states. Perhaps the recent signiﬁcant advances made in
Nav structural biology coupled with the improved high quality
screening capabilities can address this challenge to ultimately
enhance the discovery of pharmaceutically relevant Nav based
painkillers.
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